

Supplementary Data to: Appropriate Use of Anticoagulants among Nonvalvular Atrial Fibrillation Patients at a University Hospital in Thailand

Phanthaphan Sureeyathanaphat MD¹, Padoemwut Teerawongsakul¹ MD¹, Teetouch Ananwattanasuk¹ MD¹

¹ Cardiology Division, Department of Internal Medicine, Faculty of Medicine Vajira Hospital, Navamindradhiraj University, Bangkok 10300, Thailand




Figure S1 Showing percent of patients with different time in therapeutic range of INR level in patients received warfarin




Figure S2 Appropriateness of NOAC dose among each NOAC groups

Table S1 Baseline medications and therapy

Medication	% of total 783 patients
Oral anticoagulant use	68.92
Warfarin	44.00
Dabigatran	11.00
Rivaroxaban	9.80
Apixaban	4.10
Combined OAC and antiplatelet therapy	12.60
Antiplatelet therapy without OAC	14.30
Aspirin	16.60
Clopidogrel	11.50
Ticagrelor	3.10
Prasugrel	0.10
No anticoagulant/antiplatelet therapy	16.90
Other Medications	
ACEI	6.80
ARB	29.20
Beta-blocker	72.30
Calcium channel blocker	33.00
Combined beta-blocker and calcium channel blocker	30.30
Diuretics	15.20
Alpha blocker	6.00
Other antihypertensive drugs	6.60
Statin	64.10
NSAIDS	5.00
Rhythm control therapy	
Cardioversion	1.30
Amiodarone	8.40
Flecainide	3.60
Propafenone	3.20
Atrial flutter ablation	1.30

Abbreviations: ACEI, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; NSAIDS, non-steroidal anti-inflammatory drugs; OAC, oral anticoagulant

Table S2 Number (% in row) of patients with OAC therapy, stratified by CHA₂DS₂VASc score

CHA ₂ DS ₂ VASc score	OAC	No OAC	Total
0 ^a	16 (33.30%)	32 (66.70%)	48
1 ^b	47 (57.30%)	35 (42.70%)	82
≥ 2 ^c	492 (70.20%)	209 (29.80%)	701
Total	539	244	783

^aCHA₂DS₂VASc = 0, included women without additional risk factor

^bCHA₂DS₂VASc = 1, included women with one additional risk factor

^cCHA₂DS₂VASc ≥ 2, included women with two additional risk factors

Abbreviation: OAC, oral anticoagulant

Table S3 Appropriateness of NOAC dose among each NOAC groups

NOAC dosing	Dabigatran (n,%)	Rivaroxaban (n,%)	Apixaban (n,%)
Appropriate dose	34 (39.50)	39 (50.60)	25 (78.10)
Inappropriate dose	52 (60.50)	38 (49.40)	7 (21.90)
Under-dose	40 (46.50)	34 (44.20)	6 (18.80)
Over-dose	11 (12.80)	2 (2.60)	1 (3.10)
Not recommended dose	1 (1.20)	2 (2.60)	0 (0)
Total (n)	86	77	32

Abbreviations: n, number; NOAC, novel oral anticoagulant

Table S4 The incidence of ischemic stroke/SE, cardiovascular death, all-cause death in Nonvalvular atrial fibrillation patients

	Warfarin			NOAC			No OAC		
	(n)	Rate*	Person-year	(n)	Rate*	Person-year	(n)	Rate*	Person-year
1 year event									
Stroke or SE	13	3.99	325.55	1	0.53	187.6	4	1.67	239.76
Stroke	13			1			4		
Systemic embolism	0			0			0		
Cardiovascular death	1	7.46	13.41	0	0		2	18.96	10.55
All-cause death	9	2.73	329.48	2	1.05	190.09	4	1.67	239.44
5 year event									
Stroke or SE	24	1.95	1230.33	7	1.23	568.79	12	1.29	931.55
Stroke	24			6			11		
Systemic Embolism	0			1			1		
Cardiovascular death	7	0.57	1231.24	2	0.35	568.81	7	0.75	930.52
All-cause death	25	2.08	1200.31	10	1.52	656.74	17	1.90	895.1

*Incidence rate in 100 person years

Abbreviations: n, number; NOAC, novel oral anticoagulant; OAC, oral anticoagulant; SE, systemic embolism

Table S5 The incidence of bleeding at one year and 5 year

	Warfarin			NOAC			No OAC		
	(n)	Rate	Person-year	(n)	Rate	Person-year	(n)	Rate	Person-year
1 year event									
Any Bleeding	22	6.82	322.36	2	1.06	188.02	2	0.83	240.19
Severe/ life threatening	5 (ICH)			0			2 (ICH)		
Moderate bleeding	6 (5 GI, 1 non GI)			2 (GI)			0		
Mild bleeding	11			0			0		
5 year event									
Any Bleeding	45	3.73	1206.7	11	1.97	557.97	5	0.52	954.65
Severe/ life threatening	11 (ICH)			1 (ICH)			2 (ICH)		
Moderate bleeding	16 (14GI)			6 (GI)			1 (GI)		
Mild bleeding	18			4			2		

Abbreviations: GI, gastrointestinal; ICH, intracranial hemorrhage; n, number; NOAC, novel oral anticoagulant; OAC, oral anticoagulant